Cobalt Oxide Nanoparticle Synthesis by Cell-Surface-Engineered Recombinant and Potential Application for Anticancer Treatment.

Cell surface display engineering facilitated the development of a cobalt-binding hybrid . OmpC served as the molecular anchor for showcasing the cobalt-binding peptides (CBPs), creating the structural model of the hybrid OmpC-CBPs (OmpC-CP, OmpC-CF). Subsequently, the recombinant peptide's cobalt adsorption and retrieval effectiveness were evaluated at various concentrations. When subjected to a pH of 7 and a concentration of 2 mM, OmpC-CF exhibited a significantly higher cobalt recovery rate (2183.87 mol/g DCW) than OmpC-CP. The strain with bioadsorbed cobalt underwent thermal treatment at varying temperatures (400 °C, 500 °C, 600 °C, and 700 °C) and morphological characterization of the thermally decomposed cobalt nanoparticle oxides using diverse spectroscopy techniques. The analysis showed that nanoparticles confined themselves to metal ions, and EDS mapping detected the presence of cobalt on the cell surface. Finally, the nanoparticles' anticancer potential was assessed by subjecting them to heating at 500 °C in a furnace; they demonstrated noteworthy cytotoxicity, as evidenced by IC values of 59 μg/mL. These findings suggest that these nanoparticles hold promise as potential anticancer agents. Overall, this study successfully engineered a recombinant capable of efficiently binding to cobalt, producing nanoparticles with anticancer properties. The results of this investigation could have significant implications for advancing novel cancer therapies.